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Abstract  
Objetive: The objective of this paper is to analyze the equity on the financing and access to medication in Mexico, in a context of growth in the 
market of t generic drugs. It also shows the level of prices and costs of diabetes treatment.  
Materials and Methods:  This study is based on the national survey about the income and expense of households from 1998 and 2010. The 
Heckman model was used. This type of model has two stages: the first estimates the probability that the household make an expense on 
medications, while the second stage uses an Engel Curve model to explain the budgetary allocation of drug spending. 
Results:  The poorest households without social security have an expense in medication relatively higher than the rest of the population. The 
cost of diabetes treatment with drugs without patent is too high. According to the results if the drug spending of a household income increases 
by 100% it is reduced by 11.79% in 1998, while in 2010 it drops in 11.59%. The estimation of this demand equation according to the theory of the 
consumer indicates that the introduction of generic drugs has brought a wealth effect since 2010 households consume more medication, just as 
predicted. 
Conclusion:  The benefits of access to medicines may not be available on an equitable way. The poor households may not have the opportunity 
to achieve good health when it is affected by a disease which requires expensive medications or has a lifetime treatment and a great part of the 
household income is destined to it which makes them become poorer; this has a negative impact on social justice. 
Keywords: Access, inequality, inequity, financing, and prices
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Resumen
Introducción: El objetivo de este trabajo es analizar la equidad en el  financiamiento y acceso a los medicamentos en México, en un contexto de 
crecimiento en el mercado de los medicamentos genéricos. Asimismo se muestra el nivel de precios y costo del tratamiento en diabetes. 
Material y Métodos: El estudio se realiza con base a la encuesta nacional sobre el ingreso y gasto de los hogares en el período 1998-2010. Se usa el 
modelo de Heckman. Este modelo tiene dos etapas: en la primera se estima la probabilidad de que una familia realice un gasto en medicamentos, 
mientras que en la segunda se estima un modelo de la curva de Engel para explicar la asignación presupuestaria familiar en medicamentos.
 Resultados: Los hogares más pobres, sin seguridad social,  tienen un gasto en medicamentos relativamente mayor que el resto de la población. El 
costo del tratamiento para la diabetes con medicinas sin patente es muy elevado. La estimación de la curva de demanda de acuerdo a la teoría del 
consumidor indica que la introducción de medicamentos genéricos ha generado un efecto riqueza de acuerdo a los postulados de la teoría, pues se 
observa un mayor consumo de medicamentos en 2010.
 Conclusiones: Los beneficios del acceso a los medicamentos no muestran un patrón equitativo.  Las familias más pobres no tienen la oportunidad 
de lograr una buena salud cuando sufren de una enfermedad la cual requiere gastos en medicamentos costosos o tratamientos a lo largo de su vida 
lo cual le afecta a sus bajos ingresos, lo que lo hace más pobre: esto tiene un impacto negativo en la justicia social
Palabras clave: Acceso, desigualdad, inequidad, financiamiento y precios
Resumo
Objetivo: O objetivo deste artigo é analisar a equidade no financiamento e acesso a medicamentos no México, em um contexto de crescimento no 
mercado de medicamentos genéricos. Assim como o nível de preços e custos do tratamento da diabetes também é mostrado.
Materiais e métodos: O estudo foi realizado com base na enquête nacional sobre o rendimento e as despesas das famílias no período 1998-2010. É 
usado o Modelo de Heckman. Este modelo tem duas fases: em primeiro lugar estima-se a probabilidade de que uma família faça uma gastos com 
medicamentos, enquanto na segunda estima-se um modelo da curva de Engel para explicar o orçamento familiar em medicamentos.
Resultados: Os lares mais pobres, sem segurança social, têm um gasto relativamente mais elevado do que o resto da população. O custo do 
tratamento para a diabetes com medicamentos sem patente é muito alto. A estimativa da curva de demanda de acordo com a teoria do consumidor 
indica que a introdução de medicamentos genéricos gerou um efeito riqueza de acordo com os princípios da teoria, pois observa-se um maoir 
consumo de medicamentos em 2010.
 Conclusão: Os benefícios do acesso aos medicamentos não mostram um padrão equitativo. As famílias mais pobres não têm a oportunidade de 
alcançar uma boa saúde quando sofrem de uma doença que requer gastos com medicamentos caros ou tratamentos ao longo de sua vida o qual 
afetarão a sua baixa renda, tornando-o mais pobre: isto tem um impacto negativo sobre a justiça social.
Palavras-chave: Acesso, desigualdade, iniquidade, financiamento e preços
Résumé
Objetivo: Le but de cet article est d’analyser l’équité dans le financement et l’accès aux médicaments au Mexique. Aussi le niveau de prix et le coût 
du traitement du diabète est également indiqué.
Materiais e métodos: L’étude a été menée sur la base de l’enquête nationale sur le revenu et les dépenses des ménages dans la période 1998-2010. 
Le modèle Heckman a été utilisé. Ce modèle comporte deux étapes: dans la premiere étape on estime d’abord la probabilité qu’une famille fasse 
une dépense en médicaments, tandis que dans la seconde étape on estime un modèle de la courbe Engel pour expliquer la répartition du budget 
de la famille en médicaments.
Résultats: Les ménages pauvres sans dépenses de sécurité sociale ont relativement une dépense plus élevée des médicaments que le reste de la 
population. Le coût du traitement du diabète avec des médicaments sans brevet est très élevé. L’estimation de la courbe de la demande, selon la 
théorie des consommateurs indique que l’introduction de médicaments génériques a généré un effet de richesse selon les principes de la théorie, 
parce qu’on observe qu’il y a une majeure consommation des médicaments depuis 2010.
 Conclusão: Les avantages de l’accès aux médicaments ne montrent pas aucune tendance équitable. Les familles les plus pauvres ne possèdent pas 
la possibilité d’atteindre une bonne santé quand ils souffrent d’une maladie qui les fasse dépenser en médicaments ou des traitements tout au long 
de sa vie, ce qui affectera ses bas revenus et qui les rendra plus pauvres : cet effet-ci a un impact négatif sur la justice sociale.
Mots-clés: Accès, l’inégalité, l’iniquité, le financement et les prix
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Introduction 
The drug issue is a matter of which sufficient importance 
is not given on the agenda of the public health, despite 
occupying a very important place in health spending. The 
medication is a fundamental element in the prevention 
and treatment of any disease. At the beginning of the 
third millennium, a third of the population in the world 
lacks a regular and reliable access to drugs and even to 
essential medicines. The access problems are linked 
to the distance of homes to the health centers, level of 
education, cultural beliefs, infrastructure, availability, 
and forms of financing.
Developed countries, when they define the ways of 
medicine financing, as well as the financing of health 
services, avoid that this affects patients’ economy. Most 
of this expenditure is made by some scheme of co-pay or 
subsidies to vulnerable groups. But in non-industrialized 
countries, the main way of financing comes from the 
families’ income 1.
Based on the WHO (‘World Health Organization’) 
calculation, it is estimated that in developed countries 
19.5% of the health spending is used on drugs while in 
developing countries this expenditure goes on a range 
from 23.1%  to 30 2.  In addition it should be noted that 
2/3 parts of the medication is spent on public funding, 
while the opposite happens in developing countries 
where the source of funding is the households’ income, 
as in the case of Mexico where it is estimated that 85% 
of the medicine spending comes from it. Given this 
characteristic, it is important to analyze the prices of 
drugs and spending from households’ income belonging 
to a social security scheme, as well as the influence of 
socio-economic characteristics such as age, sex, house 
right and settlement in the rural or urban environment.
In the health subject it has traditionally been associated 
reduction of inequalities to equity, although this is not 
a question only of the reduction of inequalities. In this 
context, inequality in health is not synonymous with 
health inequity. The term of ‘inequalities’ in health subject 
does not reflect precisely the problem. Inequalities is 
the term used to designate differences, variations, and 
differences in the health achievements of individuals and 
groups. While ‘inequities’ refer to inequalities in health 
that are considered unfair, unacceptable or derived from 
some kind of injustice. The nobel prize in economics 
Amartya Sen points out that equity should be seen from 
a multidimensional approach where equity in health is 
not either the distribution of health or the distribution 
of health care being the most limited subject. You 
must take into account how health relates with other 
features through the allocation of resources and social 
Mercadotecnia en Salud 
arrangements3.
In general terms, health financing options are not neutral 
in relation to equity. Public funding of health services 
related to social security schemes or via tax services is a 
more equitable way of funding. On the other hand, direct 
charge is the most regressive and inequitable financing 
way. Experience indicates that fees represent a high 
economic barrier to access to health services. In this way, 
the concept of inequity in funding can be linked with the 
proportion of family income that each group spends on 
health care.
In Mexico, the society is divided into rural and urban 
environment, and into workers with formal and informal 
employment4. Similarly, on the one hand, health 
services are divided into services in social security, with 
the free provision of medications, for workers with 
formal employment. On the other hand, the services 
for the population with fewer resources and quality for 
the people without formal employment to whom the 
‘Seguro Popular’ was opened as a way of access to a basic 
package of health services5.  Half of the population has 
no formal employment, a great proportion lives in rural 
areas and has no social security coverage so they have 
to buy their drugs with their income6, to high prices, in a 
market that control the big pharmaceutical companies, 
which are beginning to face competition from generic 
drugs7.
The objective of this paper is to analyze the financing 
and access to medication in Mexico, in a context of 
generic drugs increasing share of the total drug market. 
To achieve this objective,we choose families who were 
spending on pharmaceuticals examining the relationship 
that keeps some economic, socio-economic and 
demographic characteristics and estimate how much 
spent as a proportion of their income in special the poor 
families  by comparing two years 1998 and 2010, due 
that at the end of the 90´s the generic drugs are growing.
   In this study context, we are assuming that the 
introduction of generic drugs at the end of the 90’s 
allowed the poor people to improve their access to 
medicines, nonetheless the poor people still devote a 
larger share of their income to buy essential drugs, which 
is unfair.
Materials and methods
This paper shows some characteristics on the financing 
and acess to medicines in Mexico, and the pricing 
policies of the pharmaceutical industry in the case of 
diabetes treatment. For the pricing policies we compare 
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prices of the leading drugs related with diabetes pharma 
treatment. Some features of the ways of access to 
medicines according to the expenditure of families 
are also examined. The National Survey on Household 
Incomes and Expenses (ENIGH in Spanish) is used for 
this 8. The selected years were 1998 and 2010 in order 
to check if there are significant differences in the use 
of drugs in homes since in the first year just began the 
introduction of interchangeable generic drugs and the 
second year because it is where you can see an increase 
in the use of similar and generic drugs because the 
market for them is already consolidated.
We considered a curve of Engel where it tries to explain 
the budgetary allocation of drug spending9. It is carrying 
out an estimate of demand according to the theory of the 
consumer. To illustrate the behavior of drug spending in 
households, the Heckman model was used. This model 
correct the biased estimates of the sampling selected, 
this bias is originated by the autoselection of these 
households that decide to spend in pharmaceuticals and 
those who do not10. If we use the least square method, 
instead the Heckman model, will get biased coefficients, 
due that the households that spend in drugs are part 
of the population that have monetary income to do it. 
The Heckman method consists of two stages: the first 
one is a probit model, which it is estimated to calculate 
the probability of being in the sample of individuals 
who were spending on drugs, at this stage will capture 
the effect treatment which tends to vary between 
individuals according to their characteristics (economic, 
socio-economic and demographic), this stage gets the 
inverse ratio of Mills that captures the magnitude of 
the bias, between individuals who made  a spending on 
drugs and those who do not. In this sense are considered 
two equations in the model, an equation of interest 
which we named as a curve of Engel, which explains the 
budgetary allocation of spending on medicines when 
changing consumer income, and a second equation 
that corresponds to a model of discrete choice (Probit 
or Logit) which measures the probability of being in 
the sample, which is estimated in the first stage of the 
model.
The first stage only indicates whether it occurred or not 
some drug spending (GASMED) and is based on the 
following characteristics: logarithm of common income 
(LING); The square of the logarithm of the common 
income (LING2); Male members of the household 
(HOMBRES); Female members of the household 
(MUJERES); Members of the household that are 12 years 
old or more (MAYORES); Members of the household that 
are 11 years old or less (MENORES); Affiliation to social 
security (DERHAB). The second stage indicates the 
budget allocation of household medicines (GTOMED).
Results
The results of tables 1 and 2 contain projections of 
parameters, standard errors, z-statistical, p-value of the 
contrast of significance of the variables, the inverse of 
Mills and the rank of correlation between the first and 
the second stage measured by rho. In relation to the 
results it is observed that most of the coefficients are 
statistically significant at both stages. Once the first 
stage confims that home effectively earmarked drug 
spending and that this is explained by socio-economic 
and demographic characteristics of household; it moves 
on to the second stage where shows what amount was 
assigned from household income. At this stage, you 
can see that the poorest households spend more on 
medication since LING negative coefficient indicates 
that having a higher household income brings less drug 
spending as a consequence.
Using the projection results - for both years - the 
marginal effect was calculated to have the total marginal 
effect, which indicates the percentage of drug spending 
in households. According to the results of table 3, if the 
drug spending of a household income increases by 100% 
it is reduced by 11.79% in 1998, while in 2010 it drops 
in 11.59%. The estimation of this demand equation 
according to the theory of the consumer indicates that 
the introduction of generic and similar drugs has brought 
a wealth effect since 2010 households consume more 
medication, just as predicted; while in 1998 they had a 
budget allocation of 18.6%, in 2010 it almost doubles to 
37.3 %.
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Drug spending in Mexican households by income 
decile: 1998 and 2010.
Figure 1 shows the drug spending as a percentage of 
goods and services spending by house right category. By 
1998, three groups that have an irregular distribution of 
drug spending in households were observed. The group 
that does not have a social security has a spending limit 
of 25% and a minimum expenditure of 0% it  is recorded 
in the other groups. The average was different in the 
three groups, being the group that does not have a social 
security the largest one (4%). In 2010 it is shown by 
type of house right the drug spending as a percentage 
of goods and services spending. Households without 
social security and population assigned to the ‘Seguro 
Popular’ spend the most. This indicates that despite the 
inequality in health care distribution has been reduced, 
it has no impact in the reduction of health inequity 
because access to health services via ‘Seguro Popular’ 
with a basic package of services does not guarantee that 
poor people do not have to spend more on the purchase 
of medication in comparison with people who have a 
higher income. See Figure 1.
Figure 2 shows a comparison of drug expenditure as 
a percentage of the household income in 1998 and 
2010. By 1998, it is appreciated that this spending has 
a descending behavior as the household is located in 
the upper income group. This is to say that in that year 
the poorest households were those who spent a higher 
proportion of their income on the purchase of drugs. 
The introduction of  ‘Seguro Popular’ in 2005 has not 
changed this situation since the survey of 2010 - that 
already has the information of households with such 
help- the poorest households remain being the ones 
who spend more in relative terms. In figure 2 is also 
observed that the first two deciles of income are the 
ones who spend a great part of their income on the drug 
purchasing, both beneficiaries such as those who are 
not, in a greater proportion are the last. This situation is 
interesting because it is precisely this population group 
the objective of the ‘Seguro Popular’.
Based on the information from the survey, it is estimated 
that the first two deciles spent 39% of drug spending in 
households in 1998, and this participation encreased to 
47% in 2010.
In the case of diabetes the costs were estimated to 
a daily treatment in 2010 in the case of three active 
substances: glyburide, metformin, and tolbutamide. 
The calculation was estimated to the product with 
the leading brand, generic substance and the generic 
version published in Management Science Price Guide11. 
Glibenclamide showed a difference of 5 times more in 
prices between the leading brand and its presentation at 
the international level; the difference in the metformin 
raised to 50 times more and tolbutamide recorded 
a difference of 5.5 times more. Differences between 
international prices and generic presentations in Mexico 
were reduced to half.
Conclusion
It is disturbing to think that all the benefits of access to 
medicines may not be available on an equitable way. 
According to the graphic analysis and the results of the 
projections, if ethical value judgments are added to 
this way of distribution of drug spending, the poorest 
households are the ones who actually should not happen 
to spend from their income for the purchase of medicines. 
These households may not have the opportunity to 
achieve good health when it is affected by a disease 
which requires expensive medications or has a lifetime 
treatment and a great part of the household income is 
destined to it which makes them become poorer; this 
has a negative impact on social justice. The high diabetes 
treatment cost with active popular substances shows the 
enormous power of the big pharmaceutical companies 
market, that with a poor national regulation they impose 
a heavy financial burden on the population; in a country 
like Mexico which has a segmented and inequitable 
health system and where it excludes the poor and 
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unemployed population from good health services.
The best availability of drugs on the market should 
mean a way to redistribute the access to this new 
technology and that a greater population benefited 
from this situation which would have repercussions on 
the reduction of inequities in health in Mexico. In this 
study when we compare the year 1998 just starting the 
generics market families spent approximately 11% of 
their income keeping this percentage to 2010 when this 
consolidated generics and similars market. However, 
in the last year the entry of cheaper medicines has 
produced a wealth effect because households can buy 
a greater number of medication and therefore it has a 
better access to them. Another aspect to mention is 
that in Mexico they have almost a universal coverage 
of health services wth the ‘Seguro Popular’ but this sure 
has not removed the expense in the population with low 
income. So the right that people have to achieve good 
health requires social arrangements that cover a bigger 
range than the health care distribution, where access to 
medication is not carried out according to the level of 
income of the population.
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